QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
NASDAQ:GENE

Genetic Technologies (GENE) Stock Forecast, Price & News

$0.82
+0.01 (+1.23%)
(As of 09/26/2023 ET)
Compare
Today's Range
$0.81
$0.85
50-Day Range
$0.70
$0.94
52-Week Range
$0.69
$2.40
Volume
27,225 shs
Average Volume
836,053 shs
Market Capitalization
$15.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

GENE stock logo

About Genetic Technologies (NASDAQ:GENE) Stock

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, and type 2 diabetes. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

GENE Price History

GENE Stock News Headlines

Genetic Technologies (NASDAQ: GENE)
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Genetic Technologies advances commercial plans, grows revenue
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Genetic Technologies: revolutionising preventative healthcare
Decoding genetic technologies
See More Headlines
Receive GENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter.

GENE Company Calendar

Today
9/26/2023
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GENE
Employees
60
Year Founded
1989

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.85 million
Book Value
$0.39 per share

Miscellaneous

Free Float
17,993,000
Market Cap
$15.95 million
Optionable
Optionable
Beta
1.50

Social Links

The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Simon Morriss
    Chief Exec. Officer
  • Mr. Tony Di Pietro AGIA
    B.Com, C.A., CPA, M.A.I.C.D., CFO & Company Sec.
  • Mr. Carl S. Stubbings BSc
    Chief Commercial Officer
  • Mr. Kevin Camilleri
    Chief Exec. Officer of EasyDNA
  • Mr. Paul Keith Mathieson Viney B. Bus
    FCI, FCPA, FGIA, Consultant













GENE Stock - Frequently Asked Questions

How have GENE shares performed in 2023?

Genetic Technologies' stock was trading at $0.93 at the beginning of the year. Since then, GENE stock has decreased by 10.9% and is now trading at $0.8290.
View the best growth stocks for 2023 here
.

Are investors shorting Genetic Technologies?

Genetic Technologies saw a increase in short interest in August. As of August 31st, there was short interest totaling 64,700 shares, an increase of 22.3% from the August 15th total of 52,900 shares. Based on an average trading volume of 67,700 shares, the days-to-cover ratio is currently 1.0 days.
View Genetic Technologies' Short Interest
.

What other stocks do shareholders of Genetic Technologies own?
What is Genetic Technologies' stock symbol?

Genetic Technologies trades on the NASDAQ under the ticker symbol "GENE."

Who are Genetic Technologies' major shareholders?

Genetic Technologies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Citadel Advisors LLC (0.00%).

How do I buy shares of Genetic Technologies?

Shares of GENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genetic Technologies' stock price today?

One share of GENE stock can currently be purchased for approximately $0.83.

How much money does Genetic Technologies make?

Genetic Technologies (NASDAQ:GENE) has a market capitalization of $15.95 million and generates $5.85 million in revenue each year.

How can I contact Genetic Technologies?

Genetic Technologies' mailing address is 60-66 HANOVER STREET, FITZROY C3, 3065. The official website for the company is www.gtgcorporate.com. The biotechnology company can be reached via phone at (138) 412-7000, via email at ir@gtgcorporate.com, or via fax at 011-61-3-8412-7040.

This page (NASDAQ:GENE) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -